← All indications
Intestinal Neoplasms
Tumors or cancer of the INTESTINES.
Subtype terms (6)
More specific conditions that are subtypes of Intestinal Neoplasms in the MeSH hierarchy.
- Cecal Neoplasms
- Colorectal Neoplasms
1516 drugs (399 approved, 1117 experimental)
- Duodenal Neoplasms
19 drugs (16 approved, 3 experimental)
- Ileal Neoplasms
- Immunoproliferative Small Intestinal Disease
- Jejunal Neoplasms
Drugs by status
Phase 4 trials (86)
- linaclotide
- cefpodoxime
- reconvan
- acetaminophen
- acetylsalicylic acid
- midodrine
- irinotecan
- procaine benzylpenicillin
- sodium chloride
- inactivated influenza vaccine
- alvimopan
- iopamidol
- insulin human
- Diatrizoate
- calcium alginate
- clopidogrel
- propofol
- dexmedetomidine
- cefadroxil
- weifuchun
- l-alanyl-l-glutamine
- aronia extract
- cellulose
- lidocaine
- rabeprazole
- fish oil
- berberine
- midazolam
- bismuth
- ketamine
- +56 more
Phase 3 trials (59)
- epoetin
- thalidomide
- fluticasone
- soybean oil
- human fecal microbiota
- fiber
- sufentanil
- morphine
- glucose monohydrate
- sulfasalazine
- lactobacillus delbrueckii
- telotristat ethyl
- bevacizumab
- leuprolide
- lutetium dotatate lu-177
- bifidobacterium bifidum
- plx9486
- leucovorin
- olive
- beclomethasone
- bifidobacterium lactis
- vitamin d3
- ExPEC9V
- Lactobacillus acidophilus
- famotidine
- oryza sativa
- adalimumab
- palonosetron
- Fosaprepitant
- menthol
- +29 more
Phase 2 trials (148)
- msk-2206
- gsk2251052
- vismodegib
- pyrotinib
- autologous immunoglobulin idiotype-klh conjugate vaccine
- clofarabine
- melphalan
- thiotepa
- neoantigen reactive t cells
- infigratinib
- propranolol
- vancomycin
- tazemetostat
- cisplatin
- prednisone
- dactinomycin
- fludarabine
- cyclophosphamide
- prucalopride succinate
- allogeneic hematopoietic stem cells
- dr-01
- esk981
- gemcitabine
- eflornithine
- azithromycin
- Imetelstat
- ramucirumab
- bendamustine
- aldesleukin
- doxorubicin
- +118 more
Phase 1 trials (124)
- iobenguane sulfate i-131
- bemarituzumab
- glipizide
- cb-839
- l-nmma
- bovine lactoferrin
- personalized neoantigen vaccine
- repaglinide
- sodium phenylbutyrate
- sasanlimab
- stem cells
- durvalumab
- ezetimibe
- gnc-077
- human placental derived stem cells
- streptococcus salivarius
- bryostatin
- neostigmine
- lactobacillus plantarum
- lactulose
- bifidobacterium breve
- 7-hydroxystaurosporine
- egfrbi armed atc infusions
- cilengitide
- ceftaroline fosamil
- arginine
- kx2-391
- bushen-jianpi
- pyroxamide
- inulin
- +94 more
Other trials (108)
- doxycycline
- cu64 trastuzumab
- donepezil
- bacillus subtilis
- ciprofol
- lactococcus lactis
- norepinephrine
- motexafin lutetium
- lactase
- allogeneic blood cells
- ferric ammonium citrate
- [68ga]ga-nota-rnd20
- duckweed
- fructo-oligosaccharide
- erythritol
- [68ga]ga-dota-h2d3
- cetearyl alcohol
- bifidobacteria adolescentis bd1
- dapsone
- syh2051
- cranberry
- [68ga]ga-nota-t4
- whey protein
- bilberry
- bovine colostrum
- amylmetacresol
- bezuclastinib
- alfentanil
- ceftoxamine
- turmeric
- +78 more
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (18)
- Auckland District Health Board
- National Cancer Institute (NCI)
- Canadian Cancer Trials Group
- Cancer Research Campaign
- University of Liverpool
- University of Birmingham
- Mayo Clinic
- Aichi Medical University
- Epidemiological and Clinical Research Information Network
- University of Ulsan
- University of Utah
- University of Auckland
- Sun Yat-Sen University
- University of Texas at Houston
- Aix-University of Marseille
- Sungkyunkwan University
- Counties Manukau Health
- Waitemata District Health Board
Organization Involved with Phase 2 Indications (48)
- Merck
- Pfizer
- Sanofi
- Ipsen
- Novartis
- Catalysis SL
- Hengrui Therapeutics, Inc.
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Shenzhen Hornetcorn Bio-technology Company, LTD
- Region Syddanmark
- Burzynski Research Institute
- Case Western Reserve University
- Cancer Research UK
- Centre Leon Berard
- Children's Cancer and Leukaemia Group
- Cornell University
- Harvard University
- Duke University
- University of Washington
- Hellenic Cooperative Oncology Group
- New York University
- Northwestern University
- University of Lausanne
- University of Melbourne
- University of Rochester
- University of Athens
- University of Bern
- University of Bristol
- University of Zagreb
- Societe Internationale d'Oncologie Pediatrique (SIOP)
- +18 more
Organization Involved with Phase 1 Indications (27)
- Bristol-Myers Squibb
- Amgen
- Pharmacyclics
- Blueprint Medicines Corporation
- Vion Pharmaceuticals
- National Institutes of Health (NIH)
- National Institute on Aging (NIA)
- Baylor University
- Boston University
- Temple University
- HonorHealth Research Institute
- Indiana University
- Johns Hopkins University
- Ohio State University
- Rhode Island Hospital
- Southwest Oncology Group
- Stanford University
- University of Leeds
- University of Virginia
- University of California, Davis
- University of California, San Francisco
- University of Chicago
- Vanderbilt University
- State University of New York, Buffalo
- University of Wisconsin
- Washington University in St. Louis
- University of Texas, San Antonio
Organization Involved with Other Experimental Indications (4)